Ipsen has presented long-awaited phase three results for elafibranor, a new class of medication for Primary Biliary Cholangitis. The disease, a genetic chronic liver condition, primarily affects women. Symptoms, which can take years to present, include fatigue and joint pain. Ipsen’s Jennifer Schranz noted that 51% of patients involved in the ELATIVE trial experienced significant benefits compared to 4% taking a placebo.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some